OBJECTIVE: The main objective is to evaluate the efficacy and durability of Lopinavir-ritonavir monotherapy (LPV/r-MT) in virologically-controlled HIV-positive individuals switching from combination antiretroviral therapy (cART). METHODS: Criteria to be included in this observational study were to have initiated for the first time LPV/r-MT after >=2 consecutive HIV-RNA ≤50 copies/mL achieved on a >=3 drugs-including regimen. The main end-points were time to virological rebound (VR, defined in two ways: time of first of two consecutive viral load (VL)>50 and >200 copies/ml); time to discontinuation/intensification and time to experience either a single VL >200 copies/ml or discontinuation/intensification (=treatment failure-TF). Individuals' follow-up accrued from the date of starting LPV/r-MT to event or last available VL. Kaplan-Meier curves and Cox regression analysis were used. RESULTS: 228 individuals were included; median age: 46 (IQR: 40-50) years, 36% females, 36% IDU, 25% HCV-co-infected. Median CD4 at nadir: 215 cell/mm3 (IQR:116-336); at baseline: 615 cell/mm3 (IQR: 436-768). By 36 months from switching to LPV/r-MT, the proportion of individuals with VR (confirmed VL>200 cp/ml) was 11% and with TF was 35%. In the multivariable Cox model the factors associated with a lower risk of TF was the duration of viral suppression <50 copies/mL prior to baseline (ARH=0.92, 95% CI:0.85-0.99, p=0.024, per 6 months longer) and having LPV/r as part of last cART (ARH=0.45, 95% CI:0.21-0.95, p=0.037) . CONCLUSIONS: In daily clinical practice, we confirm a relatively safe approach of simplification to LPV-MT in selected population with long-lasting virological control.

Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting / d'Arminio Monforte, A; Gianotti, N; Cozzi Lepri, A; Pinnetti, C; Andreoni, M; di Perri, G; Galli, M; Poli, A; Costantini, Andrea; Orofino, G; Maggiolo, F; Mazzarello, G; Celesia, Bm; Luciani, F; Lazzarin, A; Sighinolfi, L; Rizzardini, G; Bonfanti, P; Perno, Cf; Antinori, A.. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - STAMPA. - 19:3(2014), pp. 319-324.

Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting

COSTANTINI, ANDREA;
2014-01-01

Abstract

OBJECTIVE: The main objective is to evaluate the efficacy and durability of Lopinavir-ritonavir monotherapy (LPV/r-MT) in virologically-controlled HIV-positive individuals switching from combination antiretroviral therapy (cART). METHODS: Criteria to be included in this observational study were to have initiated for the first time LPV/r-MT after >=2 consecutive HIV-RNA ≤50 copies/mL achieved on a >=3 drugs-including regimen. The main end-points were time to virological rebound (VR, defined in two ways: time of first of two consecutive viral load (VL)>50 and >200 copies/ml); time to discontinuation/intensification and time to experience either a single VL >200 copies/ml or discontinuation/intensification (=treatment failure-TF). Individuals' follow-up accrued from the date of starting LPV/r-MT to event or last available VL. Kaplan-Meier curves and Cox regression analysis were used. RESULTS: 228 individuals were included; median age: 46 (IQR: 40-50) years, 36% females, 36% IDU, 25% HCV-co-infected. Median CD4 at nadir: 215 cell/mm3 (IQR:116-336); at baseline: 615 cell/mm3 (IQR: 436-768). By 36 months from switching to LPV/r-MT, the proportion of individuals with VR (confirmed VL>200 cp/ml) was 11% and with TF was 35%. In the multivariable Cox model the factors associated with a lower risk of TF was the duration of viral suppression <50 copies/mL prior to baseline (ARH=0.92, 95% CI:0.85-0.99, p=0.024, per 6 months longer) and having LPV/r as part of last cART (ARH=0.45, 95% CI:0.21-0.95, p=0.037) . CONCLUSIONS: In daily clinical practice, we confirm a relatively safe approach of simplification to LPV-MT in selected population with long-lasting virological control.
2014
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/156503
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact